{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:19:24Z","timestamp":1748359164936,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["NMRPG8G6102"],"award-info":[{"award-number":["NMRPG8G6102"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8F0221"],"award-info":[{"award-number":["CMRPG8F0221"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10620-021-07128-6","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T13:02:43Z","timestamp":1625835763000},"page":"3402-3411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir"],"prefix":"10.1007","volume":"67","author":[{"given":"Hsin-Wei","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hao","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-8133","authenticated-orcid":false,"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"7128_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335\u2013352.","journal-title":"J Hepatol"},{"key":"7128_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet (London, England) 2009;373:582\u2013592.","journal-title":"Lancet (London, England)"},{"key":"7128_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"issue":"67","key":"7128_CR4","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. Electronic address, European Association for the Study of the L. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address, European Association for the Study of the L. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017:370\u2013398.","journal-title":"J Hepatol"},{"key":"7128_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, Md.) 2018;67:1560\u20131599.","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"7128_CR6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/hep.26549","volume":"58","author":"WJ Jeng","year":"2013","unstructured":"Jeng WJ, Sheen IS, Chen YC et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888\u20131896.","journal-title":"Hepatology"},{"key":"7128_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","volume":"61","author":"CH Chen","year":"2014","unstructured":"Chen CH, Lu SN, Hung CH et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014;61:515\u2013522.","journal-title":"J Hepatol"},{"key":"7128_CR8","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen CH, Hung CH, Hu TH et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic HBV infection. Clin Gastroenterol Hepatol 2015;13:1984\u20131992.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7128_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/jvh.12851","volume":"25","author":"CH Chen","year":"2018","unstructured":"Chen CH, Hsu YC, Lu SN et al. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat 2018;25:590\u2013597.","journal-title":"J Viral Hepat"},{"key":"7128_CR10","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185\u2013S195.","journal-title":"Hepatology"},{"key":"7128_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","volume":"143","author":"SJ Hadziyannis","year":"2012","unstructured":"Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629\u2013636.","journal-title":"Gastroenterology"},{"key":"7128_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"T Berg","year":"2017","unstructured":"Berg T, Simon K-G, Mauss S et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study. J Hepatol 2017;67:918\u2013924.","journal-title":"J Hepatol"},{"key":"7128_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","volume":"68","author":"WJ Jeng","year":"2018","unstructured":"Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2018;68:425\u2013434.","journal-title":"Hepatology"},{"key":"7128_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","volume":"24","author":"CH Chen","year":"2018","unstructured":"Chen CH, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect 2018;24:997\u20131003.","journal-title":"Clin Microbiol Infect"},{"key":"7128_CR15","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1053\/j.gastro.2018.03.066","volume":"154","author":"YF Liaw","year":"2018","unstructured":"Liaw YF, Jeng WJ, Chang ML. HBsAg kinetics in retreatment decision for off-therapy hepatitis B flare in HBeAg-negative patients. Gastroenterology 2018;154:2280\u20132281.","journal-title":"Gastroenterology"},{"key":"7128_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531\u2013561.","journal-title":"Hepatol Int"},{"key":"7128_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"European Association for Study of Liver","year":"2015","unstructured":"European Association for Study of Liver. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237\u2013264.","journal-title":"J Hepatol"},{"key":"7128_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/00365521.2018.12027892","volume":"38","author":"CM Lee","year":"2003","unstructured":"Lee CM, Chen CH, Lu SN et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003;38:95\u2013101.","journal-title":"Scand J Gastroenterol"},{"key":"7128_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337\u2013344.","journal-title":"Biometrics"},{"key":"7128_CR20","doi-asserted-by":"publisher","first-page":"e0222221","DOI":"10.1371\/journal.pone.0222221","volume":"14","author":"TL Ma","year":"2019","unstructured":"Ma TL, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS ONE 2019;14:e0222221.","journal-title":"PLoS ONE"},{"key":"7128_CR21","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","volume":"18","author":"SM Chiu","year":"2020","unstructured":"Chiu SM, Kuo YH, Wang JH et al. Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy. Clin Gastro Hepatol 2020;18:2989\u20132997.","journal-title":"Clin Gastro Hepatol"},{"key":"7128_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3851\/IMP3256","volume":"23","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M et al. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther 2018;23:677\u2013685.","journal-title":"Antivir Ther"},{"key":"7128_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/gutjnl-2014-307596","volume":"64","author":"P Lampertico","year":"2015","unstructured":"Lampertico P. Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue? Gut 2015;64:526\u2013552.","journal-title":"Gut"},{"key":"7128_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.15053","volume":"49","author":"MT Kuo","year":"2019","unstructured":"Kuo MT, Hu TH, Hung CH et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019;49:218\u2013228.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07128-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-07128-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07128-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T19:25:08Z","timestamp":1656357908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-07128-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["7128"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-07128-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}